We present epigenetic inhibitors as a novel therapeutic intervention for MM by further highlighting the potential use of BMI-1 inhibitors alone or in combination with other epigenetic inhibitors directed to PRC2/EZH2 or BET bromodomains in targeting the malignant MM cell. The gene discussed is DNER; the disease is Miyoshi myopathy.